Proteomic profiling of hepatitis B virus-related hepatocellular carcinoma with magnetic bead-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Proteomic techniques are promising strategies in the surveillance of hepatocellular carcinoma (HCC). This study aimed to investigate the serum profiling with magnetic bead (MB) and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) and to further identify the biomarkers for HCC. Serum samples from 80 chronic hepatitis B (CHB) patients, 94 HCC concomitant with HBV patients and 24 healthy subjects were examined by MALDI-TOF MS after peptide enrichment on MBs. Based on the genetic algorithm, diagnostic models for HCC were established between 30 HCC patients and 24 healthy subjects/30 CHB patients. Validations were done with the remaining cases. Markers in the models were identified through liquid chromatography (LC)/MS-MS. The three groups were well separated from each other and two discrimination models were established for HCC. The overall recognition capability of these two models was 96.25% and 93.33%, respectively. Validations showed the misdiagnosis ratio for HCC was 1.6% and 23.4%, respectively. The identified biomarkers for HCC included prothrombin precursor (fragment), calcium-dependent secretion activator 1, Baculoviral inhibitor of apoptosis  repeat-containing protein 6, etc. MB-based MALDI-TOF MS is applicable in identifying the serum biomarkers and can be used in the surveillance of HCC among HBV-infected patients.

[1]  W. Skarnes,et al.  The Birc6 (Bruce) gene regulates p53 and the mitochondrial pathway of apoptosis and is essential for mouse embryonic development. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  S. Baumann,et al.  Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. , 2005, Clinical chemistry.

[3]  M. Sherman,et al.  Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population , 1995, Hepatology.

[4]  D. Machin,et al.  Simple clinical prognostic model for hepatocellular carcinoma in developing countries and its validation. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T. Martin,et al.  Role of CAPS in Dense‐Core Vesicle Exocytosis , 2002, Annals of the New York Academy of Sciences.

[6]  X. Wang,et al.  The role of cytokines in hepatocellular carcinoma , 2006, Journal of leukocyte biology.

[7]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[8]  E. Diamandis.  Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool , 2004, Molecular & Cellular Proteomics.

[9]  Rapid determination of serological cytokine biomarkers for hepatitis B virus-related hepatocellular carcinoma using antibody microarrays. , 2011, Acta biochimica et biophysica Sinica.

[10]  R. Irizarry,et al.  Serum protein MALDI profiling to distinguish upper aerodigestive tract cancer patients from control subjects. , 2003, Journal of the National Cancer Institute.

[11]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[12]  A. Olshen,et al.  Differential exoprotease activities confer tumor-specific serum peptidome patterns. , 2005, The Journal of clinical investigation.

[13]  M. Kostrzewa,et al.  Mass spectrometry-based clinical proteomics. , 2003, Pharmacogenomics.

[14]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[15]  Yan Liu,et al.  Global Burden of Aflatoxin-Induced Hepatocellular Carcinoma: A Risk Assessment , 2010, Environmental health perspectives.

[16]  R. Pitts,et al.  A novel approach using MALDI-TOF/TOF mass spectrometry and prestructured sample supports (AnchorChip Technology) for proteomic profiling and protein identification. , 2008, Methods in molecular biology.

[17]  Richard M Weinshilboum,et al.  Pharmacogenomics and reducing the frequency of adverse drug events. , 2003, Pharmacogenomics.

[18]  E. Holland,et al.  Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. , 2004, Analytical chemistry.

[19]  P. Johnson,et al.  The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. , 2001, Clinics in liver disease.

[20]  B. Bell,et al.  The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.

[21]  H. Ohta,et al.  Measurement of immunoreactive prothrombin precursor and vitamin-K-dependent gamma-carboxylation in human hepatocellular carcinoma tissues: decreased carboxylation of prothrombin precursor as a cause of des-gamma-carboxyprothrombin synthesis. , 1990, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[22]  J. Hoofnagle,et al.  Elevations in serum alpha‐fetoprotein levels in patients with chronic hepatitis B , 1989, Cancer.

[23]  Wayne F. Patton,et al.  A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. , 2007, Clinical chemistry.

[24]  M. Kew.  Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. , 2010, Pathologie-biologie.

[25]  H. Griffiths,et al.  The use of proteomics for the assessment of clinical samples in research. , 2004, Clinical biochemistry.

[26]  Chun-Ta Liao,et al.  Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. , 2005, Clinical chemistry.

[27]  L. Cazares,et al.  Differential Capture of Serum Proteins for Expression Profiling and Biomarker Discovery in Pre‐ and Posttreatment Head and Neck Cancer Samples , 2008, The Laryngoscope.

[28]  Kevin R Coombes,et al.  Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  S. Jentsch,et al.  Dual role of BRUCE as an antiapoptotic IAP and a chimeric E2/E3 ubiquitin ligase. , 2004, Molecular cell.

[30]  Jeffrey S. Morris,et al.  A comprehensive approach to the analysis of matrix‐assisted laser desorption/ionization‐time of flight proteomics spectra from serum samples , 2003, Proteomics.

[31]  Chibo Liu,et al.  MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of hepatocellular carcinoma. , 2010, American journal of clinical pathology.